{"id":"W3133838590","doi":"10.1016/j.jtho.2021.02.010","title":"Crizotinib in Patients With MET-Amplified NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Exelixis; Revolution Medicines; Foundation Medicine; Sierra Oncology; Pfizer; Incyte; Astex Pharmaceuticals; Bayer Fund; AstraZeneca; Novocure; Merck KGaA; Jounce Therapeutics; Ariad Pharmaceuticals; Takeda Pharmaceutical Company; Amgen; Roche; Spectrum Pharmaceuticals; Merck; GlaxoSmithKline; Array BioPharma; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Fluorescence in situ hybridization; Internal medicine; ROS1; Retrospective cohort study; Gene duplication; Gastroenterology; Progression-free survival; Hazard ratio; Oncology; Confidence interval; Overall survival; Adenocarcinoma; Lung cancer; Gene; Cancer; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001481467,0.00007507085,0.0003538899,0.0001288444,0.00002428689,0.000007454973,0.00004178917,0.00006645669,0.0001855218],"category_scores_gemma":[0.00009685757,0.00004973239,0.00006386461,0.0002062656,0.00002803612,0.00007823035,0.00001415488,0.0002126402,0.000008297559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00032844,"about_ca_system_score_gemma":0.0009325574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006239276,"about_ca_topic_score_gemma":0.0000257952,"domain_scores_codex":[0.9991839,0.00007846681,0.0003200283,0.00009531993,0.0001870383,0.0001352465],"domain_scores_gemma":[0.9990696,0.00006996074,0.0002288662,0.000109566,0.0004179748,0.0001040815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00527274,0.003853322,0.588481,0.00008129797,0.0008123998,0.002841366,0.001349609,0.00004537875,0.0004460674,0.0001931479,0.002263041,0.3943606],"study_design_scores_gemma":[0.007749116,0.005573572,0.9417719,0.0002807512,0.0009076201,0.0005691532,0.0007881198,0.000003431122,0.0009840607,0.0002193579,0.04105024,0.0001027142],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873625,0.000312685,0.0001768811,0.002623146,0.0003572547,0.0001271665,0.000004124761,0.000004667282,0.009031571],"genre_scores_gemma":[0.9891079,0.0000205754,0.009344929,0.0006825133,0.0001132104,0.000003489396,0.00001214974,0.00001086577,0.0007043517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3942579,"threshold_uncertainty_score":0.2031334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0194702299251419,"score_gpt":0.4345962996276041,"score_spread":0.4151260697024622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}